From June 13-15, we will host over 50 live showcases online with 60 assets from seeking for China or global licensing partners. The first day showcase will start to broadcast at 9 a.m. on June 13th (China time).
View full agenda here: https://biotochina.org/agenda/
Dial-in link
Register zoom in advance
https://us02web.zoom.us/webinar/register/WN_znLZ6rBISGmhBIEQnvbmfg
If you already registered, please search for confirmation emails from zoom.us
DAY 1 Innovative Drug Out-Licensing Roadshow
Nanokide Theraputics
Nanokide Theraputics is a spin-off of the University of the Basque Country based in Spain. It is focused on anticancer drug development combining our own naoparticle technology (patented by Nnaokide Therapeutics) and miRNA and mRNA technology. The pipeline is composed of 3 products (antiangiogenic, antiCSC and immunotherapy) in different development phases.
Nanokide therapeutics是巴斯克大学的分拆公司，总部设在西班牙。它专注于抗肿瘤药物的研发，拥有纳米颗粒技术(公司拥有自主知识产权)、miRNA和mRNA技术平台。公司管线由3个处于不同开发阶段的产品(抗血管生成、抗造血干细胞和免疫治疗)组成。
Immunosynth
Immunosynth is a startup in the San Francisco Bay area, dedicated to the development of T cell receptor (TCR) based immunotherapy to treat solid tumors. They are developing a novel TCR-NK platform and soluble TCR BiTE, both based on the TCRs we have identified through our proprietary TCR discovery technology that targets the shared tumor driver mutations. The TCR has been functionally validated in vitro.
Immunosynth是旧金山湾区的一家初创公司，致力于开发基于T细胞受体(TCR)的免疫疗法来治疗实体肿瘤。目前正在开发一种新的TCR- NK平台和可溶性的TCR BiTE，这些TCR是是基于公司自有的TCR发现技术发现，靶向共同的肿瘤驱动突变。该TCR已经过体外研究验证。
FivepHusion
FivepHusion is a private Australian biotechnology company headquartered in New South Wales, founded in 2018. They are developing Deflexifol™, a novel advanced clinical-stage enhanced drug reformulation for a range of adult and childhood cancers with significant unmet medical needs. Their goal is to optimize chemotherapy to improve patient treatment outcomes and quality of life.
FivepHusion是一家总部位于澳大利亚新南威尔士州的私人生物技术公司，成立于2018年。公司正在开发Deflexifol™是一种新颖的临床阶段的增强型药物改良技术，用于治疗一系列未满足医疗需求的成人和儿童癌症。公司的目标是优化化疗方案，改善患者的治疗效果和生活质量。
AUM Biosciences
AUM Biosciences is a global clinical-stage oncology company focused on advancing a clinical-stage pipeline of precision oncology therapeutics designed to deploy multi-faceted inhibition strategies to reverse cancer resistance. AUM001 is a selective and synergistic MNK inhibitor as shown in current studies and has initiated Phase 2 study enrollment. AUM601 is a promising therapy for TRK fusions and mutations within the kinase domain and is on track to enter Phase 2 planning. AUM302 is a potentially first-in-class macrocyclic oral kinase inhibitor.
AUM Biosciences是一家全球临床阶段的肿瘤学公司，专注于推进一系列精准肿瘤治疗的临床阶段管线，旨在采用多方面的抑制策略来逆转癌症耐药性。AUM001是一种选择性和协同作用的MNK抑制剂，目前的研究显示其疗效显著，并已启动第2阶段的招募入组。AUM601是一种有希望的TRK融合基因和激酶领域突变的治疗方法，正计划进入第2阶段的规划。AUM302是一种潜在的首创大环口服激酶抑制剂。
Chimeric Therapeutics
Chimeric Therapeutics is a clinical-stage cell therapy company focused on bringing the promise of cell therapy to life for more patients with cancer. Chimeric’s world-class team of cell therapy pioneers and experts is focused on the discovery, development, and commercialization of the most innovative and promising cell therapies.CHM 1101 (CLTX CAR T) PHASE 1 CLINICAL TRIAL Phase 1 Study to Evaluate Chimeric Antigen Receptor (CAR) T Cells Incorporating a Chlorotoxin Tumor-targeting Domain for Patients with MMP2+ Recurrent or Progressive Glioblastoma
Chimeric Therapeutics是一家临床阶段的细胞疗法公司，致力于为更多癌症患者带来细胞疗法的希望。Chimeric拥有世界级的细胞疗法先驱和专家团队，专注于发现、开发和商业化最具创新和有前景的细胞疗法。其资产CHM 1101（CLTX CAR T）目前的1期临床试验，旨在评估携带氯毒素肿瘤靶向结构域的嵌合抗原受体（CAR）T细胞，用于治疗MMP2+复发或进展性胶质母细胞瘤患者。
CellAct
CellAct was founded in 2007 as a venture-backed biotech. It focuses on targeted therapies for cancer. The CEO is supported by a team of pharmaceutical industry development experts. A Phase III program in Biliary Tract Cancer is ready to begin. In 2017, in a deal worth up to $250M, CellAct licensed the program to MundiPharma /Purdue who focused on finalizing the commercial-ready CMC process and preparing for the registrational trial.
CellAct成立于 2007 年，是一家风险投资支持的生物技术公司，专注于癌症靶向治疗。核心产品为多重耐药泵 MDR1 和拓扑异构酶 II 抑制剂的双重抑制剂，用于胆道癌治疗的III期临床试验即将开始。该公司管理团队均具有丰富药物研发及商业化经验。该公司曾将该项目许可给了 MundiPharma/Purdue，该交易总金额价值 2.5 亿美元。
Bilayer Therapeutics
Bilayer Therapeutics seeks to develop bile acids as first-in-class therapies to treat diseases of the colon using a GLP-1-based mechanism of action and a unique and proprietary colonic delivery technology. First in its portfolio is BL-010, a therapy for chronic constipation as beachhead indication followed by BL-050, an orally available therapy for metabolic disorders such as obesity and diabetes which acts through increasing native levels of GLP-1.
Bilayer Therapeutics致力于利用基于GLP-1机制的胆汁酸及独特专利的结肠递送技术，将其作为首创疗法开发，用于治疗结肠疾病。其产品组合中首个项目是BL-010，首个适应症用于治疗慢性便秘； BL-050是一款口服药物，增加GLP-1 的天然水平治疗代谢性疾病，如肥胖症和糖尿病。
Zytoprotec
Zytoprotec is a late-stage biotech company, located in Vienna, Austria, that develops products for peritoneal dialysis (PD). Their lead product, PDprotec® has successfully completed a double-blind clinical phase II study and is now ready for a phase III clinical trial in either Europe, the US, or Asia. They have an orphan drug status from the US-FDA and positive feedback on the planned phase III trial from both the US-FDA as well as the European EM.
Zytoprotec是一家位于奥地利维也纳的后期生物科技公司，致力于开发腹膜透析（PD）产品。他们的核心产品PDprotec®已经成功完成了双盲的临床二期研究，并准备进行三期临床试验，临床中心会包括欧洲、美国和亚洲。产品获得了美国FDA的孤儿药认证，三期试验设计获得了美国FDA和欧洲EM的积极反馈。
REDNVIA
REDNVIA, as a cardiovascular biotechnology company, focuses on satisfying the high unmet medical needs of cardiovascular diseases with a 2-way development strategy. Its asset RNV-1001, a DPP-4 inhibitor, has been shown to be effective in reducing aortic valve stenosis calcification.
REDNVIA作为一家心血管领域的生物技术公司，专注心血管疾病高度未满足的医疗需求，并采取双轨发展战略。RNV-1001是一种DPP-4抑制剂，已被证明其减少主动脉瓣狭窄钙化的有效性。
Astrocyte Pharmaceuticals
Astrocyte Pharmaceuticals is pursuing an innovative neuroprotective strategy of enhancing mitochondrial energy production in astrocytes to protect and repair damaged neurons and advancing breakthrough therapeutic agents for treating brain injury patients. AST-004 has a wide intervention window Phase 1A study in 52 healthy subjects complete with no safety concerns. Phase 1B study in healthy subjects ongoing.
Astrocyte Pharmaceuticals正在追求一种创新的神经保护策略，产品可以增强线粒体 ATP 的产生，来保护和修复受损的神经元，用于治疗脑损伤患者。AST-004在52名健康受试者中进行的临床1A期研究已经完成，未发生安全隐患，具有广泛的干预窗口。目前在健康受试者中进行1B期研究。
WEX Pharmaceuticals Inc.
WEX Pharmaceuticals Inc. is a biopharmaceutical company developing Halneuron® (Tetrodotoxin or TTX), for the treatment of neuropathic and nociceptive pain. Halneuron is currently being tested in a Phase 2 multinational clinical trial and is approved by the US Food Drug Administration and Health Canada to commence pivotal Phase 3 clinical trials for moderate to severe Chemotherapy-Induced Neuropathic Pain.
WEX Pharmaceuticals Inc.是一家生物制药公司，开发Halneuron®(河豚毒素或TTX)，用于治疗神经性和痛觉性疼痛。Halneuron目前正在进行一项2期的多国临床试验，并已获得FDA和加拿大卫生部的批准，开始针对中度至重度化疗引起的神经性疼痛的关键性3期临床试验。
NuvOx
NuvOx focuses on diseases where hypoxia plays critical roles such as in oncology, stroke, and the acute respiratory distress syndrome (ARDS). Their technology is from the founder’s groundbreaking work on selling contrast agents, a major product of a $4bn market cap public company. Dodecafluoropentane is the active pharmaceutical ingredient of the product NanO2. NanO2 brings First-In-Class, disruptive treatment for multiple conditions.
NuvOx专注于由缺氧导致的疾病，例如肿瘤学、中风和急性呼吸窘迫综合征 (ARDS)。他们的技术来自创始人在销售造影剂方面的开创性工作，其造影剂是一家市值 40 亿美元的上市公司的主要产品。 十二氟戊烷是产品 NanO2 的药物活性成分。 NanO2 为多种病症带来了一流的、颠覆性的治疗方案。
Nanjing Chuangte Pharmaceutical Technology Co., Ltd.
Nanjing Chuangte Pharmaceutical Technology Co., Ltd. was founded in February 2019. The company is an innovative biotech company specializing in research and development of new drugs. Nanjing Chuangte focuses on cancers, cardiovascular and respiratory diseases, and is committed to providing innovative products so as to consistently provide patients with health services, and create value for customers. The company also employed professors, researchers, senior engineers, and many scientific consultants. The pipeline comprises 19 new drugs in development, with 3 new drugs in clinical trials and all drugs are showing satisfactory data in clinical trials.
南京创特医药科技有限公司成立于2019年2月，是一家专门从事新药研发、技术转让、医药新产品产业化的创新型生物医药企业。创特医药聚焦肿瘤、脑血管及呼吸系统疾病，致力于提供创新型的产品，通过创新驱动医药产业资源的整合，持续为患者健康服务，为客户创造价值。通过持续的研发投入和不懈努力，公司目前已建立起包括19个在研药物的产品研发管线，其中3个创新药进入临床阶段，且临床进展顺利。
Evive Biotech
Evive Biotech, a subsidiary of Yifan Pharmaceutical, is a global biopharmaceutical company devoted to developing a portfolio of novel biological therapies for patients worldwide. They leverage their proprietary technology platforms to advance a series of innovative drug candidates for oncology, inflammatory, and metabolic diseases. Founded in 2004, we currently have operations in the US, EU, Singapore, and China. Evive adopts a holistic approach to drug development, combining exceptional preclinical and clinical research capabilities with our world-class in-house manufacture and regulatory expertise Ryzneuta™ (F-627) is a novel, long-acting granulocyte colony-stimulating factor (G-CSF) intended to treat chemotherapy-induced neutropenia (CIN) in patients with cancer.
亿一生物科技是亿帆药业的子公司，是一家致力于为全球患者开发新型生物疗法的全球性生物制药公司。他们利用自己的专有技术平台推进一系列针对肿瘤、炎症和代谢疾病的创新候选药物。公司成立于2004年，目前在美国、欧盟、新加坡和中国设有子公司。Evive具备全流程的研究体系，将卓越的临床前和临床研究能力与世界一流的内部生产和监管专业知识相结合。Ryzneuta™(F-627)是一种新型的长效粒细胞集落刺激因子(G-CSF)，用于治疗癌症患者化疗诱导的中性粒细胞减少症(CIN)。
Qurebio
Qurebio is a research-oriented company dedicated to the development of innovative macromolecular biopharmaceuticals. The goal is to develop therapeutic drugs for challenging diseases such as cancer and autoimmune disorders, benefiting patients in China and around the world. Founded by experienced scientists from Eli Lily and Amgen, the company has built up a series of proprietary technologies for engineered bio-macromolecules and established ongoing cooperation with industrial partners including Hengrui Pharmaceuticals. With a track record of global drug development, the founding team has a profound understanding of oncology-immunology and rich experience.
启愈生物是一家专注于创新大分子生物药的研发型公司，目标是针对中国和世界的难治的癌症、自身免疫等疾病领域开发治疗新药、造福患者。公司具备强大的自研能力，已经建立数个创新平台，先后与恒瑞医药等数个业内知名生物技术公司达成一系列早期研发合作。公司创始团队曾在安进、礼来、恒瑞等海内外知名药企任职20余年，有深刻的肿瘤免疫学理解及丰富的生物医药领域产业经验。
Immunophage Biomedical Co Ltd
Immunophage Biomedical Co Ltd is a global-clinical stage biopharmaceutical company focusing on innovating and developing the next generation drug for unmet medical needs. Founded and managed by seasoned executives in the biopharma industry, Immunophage is backed by many renowned investors. The company has developed a pipeline of globally innovative molecules, covering a wide range of innovative targets with a particular focus on oncology, autoimmune diseases, and neurodegenerative diseases. The company has built strong capability for both small and large molecular platforms. Based on our own platform and effort, currently, we have two self-developed assets in the clinical stage (IPG1094 and IPG7236). Meanwhile, we have a number of global leading innovative molecules under research and development. The company endeavors to advance at least two potentially innovative and differentiated global molecules into the clinic each year, providing clinical benefits to patients worldwide.
南京艾美斐生物医药科技有限公司是一家临床阶段的生物制药公司，专注于创新药研发。艾美斐由两位生物制药行业经验丰富的高管创立和管理，并获得许多知名投资者的支持。
公司注重研究疾病的致病机理，深入发掘新靶点，围绕恶性肿瘤、自身免疫性疾病、神经退行性疾病等重大疾病开展新药开发。公司拥有小分子和大分子药物筛选和测试平台进行药物开发，目前第一梯队两个项目IPG1094&IPG7236处于临床Ⅰ-Ⅱ期阶段。公司致力于每年将至少两种具有创新潜力和差异化的全球分子推向临床，为全球患者提供新的支持。
Sound Pharmaceuticals
Sound Pharmaceuticals is an innovation-driven biopharmaceutical company initiated by the Nobel Prize-winning team, dedicated to the discovery, development, clinical development, and commercialization of innovative drugs on a global scale. The company has built a series of internationally leading core technology platforms such as monoclonal antibody screening, antibody humanization, molecular activity detection and optimization, protein production and purification, and bispecific antibodies. Its asset is a highly differentiated CD38 monoclonal antibody, which is the only non-toxic CD38 monoclonal antibody in the world, and its effect on killing tumor cells is significantly better than that of similar products that have been marketed. The CD38 monoclonal antibody was approved by the FDA and will enter the clinical trial stage in October 2022.
非同生物是一家由诺奖团队人员发起的创新驱动型生物制药公司，致力于创新药物的发现、开发，以及在全球范围内的临床研发及商业化。公司搭建了单克隆抗体筛选、抗体人源化、分子活性检测和优化、蛋白质生产和纯化、双特异性抗体等一系列国际领先的核心技术平台。其资产为高分化CD38单克隆抗体，是全球唯一无毒的CD38单克隆抗体，杀伤肿瘤细胞的效果明显优于已上市同类产品。CD38单克隆抗体获FDA批准2022年10月进入临床试验阶段。
Shanghai Novamab Biopharmaceuticals Co., Ltd.
Shanghai Novamab Biopharmaceuticals Co., Ltd. is an innovative biopharmaceutical enterprise dedicated to the research and development of single-domain antibody (sdAb) drugs. Novamab has independently created five core technology platforms: sdAb rapid screening platform, Pichia pastoris-based CMC platform, biological drug inhalation platform, long-acting sdAb platform, and bispecific/multispecific sdAb platform. Novamab has developed more than 10 sdAb drugs covering respiratory, anti-infection, ophthalmology, and oncology. LQ036 (anti IL-4Rα) and LQ043 (anti TSLP) have overturned the existing treatment methods for respiratory diseases, both of which are the world’s first inhalable sdAb drug for their respective target.
上海洛启生物医药技术有限公司是一家致力于纳米抗体药物研发及产业化的创新型生物制药企业。洛启生物自主创建了五大核心技术平台：纳米抗体快速筛选平台、毕赤酵母CMC工艺开发平台、吸入式大分子药物研发平台、纳米抗体长效平台和纳米抗体双抗平台。
洛启生物已经开发了数十种纳米抗体药物，管线涵盖呼吸系统、抗感染、眼科和肿瘤等领域。在研产品LQ036及LQ043颠覆了现有呼吸类疾病的治疗方式，均为同靶点的全球首创吸入式纳米抗体药物。
Spekar Therapeutics
Spekar Therapeutics is a specialty pharmaceutical company focused on the licensing, development, and commercialization of value-added formulations in the central nervous system area. They optimize established molecules by reformulating or repositioning them for new indications with improved clinical benefit. Their goal is to provide patients with products with improved safety, efficacy, and convenience over existing treatments, while delivering these products in a cost-effective manner. A new extended-release formulation of an existing antidepressant is for collaboration.
Spekar Therapeutics该公司是一家专注于开发中枢神经系统领域药物的开发、改良，和商业化的专业制药公司。该公司通过针对药物现有的分子和特性进行重新配方或重新定位来优化药物，或使其应用于新的适应症，从而提高其临床价值和效益。他们的目标是为患者提供比现有治疗更安全、更有效和更方便的高性价比产品。一种现有抗抑郁药物的新缓释制剂，市场上该药物主要以速释片剂形式出售，但速释片剂有白天镇静的副作用。
ABM Therapeutics
ABM Therapeutics is a research and development company established by a group of scientists and entrepreneurs with a successful track record in enterprise operations. The company is dedicated to developing first-in-class innovative drugs for global patients. It focuses on providing small molecule targeted therapies for primary and secondary brain cancers, including glioblastoma, as well as brain metastases from lung cancer, breast cancer, or melanoma. Their asset, ABM-1310, is expected to become the best-in-class drug in its category. The candidate drug received clinical trial approvals from the US FDA and China’s NMPA in November 2019 and November 2021, respectively. Clinical Phase I trials are currently progressing smoothly in the United States.
璧辰医药是一家拥有企业运作成功经验的一批科学家和企业家建立的，为全球患者开发一流创新药物的研发公司。公司专注于提供治疗包括脑胶质瘤在内的原发性和继发性脑癌，以及肺癌、乳腺癌或黑色素瘤脑转移的小分子靶向疗法。其资产ABM-1310预期能够成为同类中最好的药物。该候选药物分别于2019年11月和2021年11月获得美国FDA和中国NMPA临床试验许可，在美国的临床I期试验正在顺利进行中。
Revolmmune Therapeutics
Revolmmune Therapeutics takes the research and development and application of viral vectors and tumor immunotherapy technology as a breakthrough, simultaneously transforms the latest foreign tumor immunotherapy technology, actively promotes innovative tumor immunotherapy technology, and provides cutting-edge precision treatment solutions for cancer patients. The company’s research team has long been committed to the research of oncolytic viruses and has many core technologies, including a number of patents such as recombinant enteroviruses and molecular immunomodulators.
上海行深生物科技有限公司以病毒载体及肿瘤免疫治疗技术研发和应用为突破口，同步转化国外最新的肿瘤免疫治疗技术，积极推动创新性肿瘤免疫治疗技术，为肿瘤患者提供前沿的精准治疗方案。公司研究团队长期致力于溶瘤病毒的研究，拥有众多核心技术，其中包括重组肠道病毒、分子免疫调节剂等多项专利。
BioToChina.org 